Intratumoral delivery of transcon™ tlr7/8 agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction

HIGHLIGHTS

• who: Luis Alejandro Zu00fau00f1iga from the Ascendis Pharma A/S, Hellerup, Copenhagen, Denmark have published the article: Intratumoral delivery of TransConu2122 TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction, in the Journal: (JOURNAL)
• what: Taken together, the described studies provide proof of principle that a single dose of TransCon TLR7/8 Agonist mediates anti-tumor efficacy via sustained delivery of resiquimod to the tumor site while avoiding high systemic exposure and reducing the risk of AEs.
• how: Statistics Repeated measures 2-way analysis . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.